
|Articles|November 26, 2012
FDA panel votes against OTC use of OAB agent
An FDA advisory panel voted against making oxybutynin transdermal patch (Oxytrol, Merck and Watson Pharma) available over-the-counter (OTC) for overactive bladder (OAB) in women, Medpage Today reported.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Drug Promotion on Social Media Lacks Risk Information
2
Pharmacy Law Lowdown: Independent Pharmacy’s Most Challenging Legal Concerns
3
NCPA, USC Launch Pharmacy Desert Identification Tool
4
Results Show Reductions in Sinus Opacification With Dupilumab for Allergic Fungal Rhinosinusitis
5













































































































































